---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045840"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:42:37.722163+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003

## Summary
- Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.
- Lead candidate EB-003 shows oral bioavailability and brain exposure; IND filing expected H2 2025.
- Out-licensed radiation dermatitis product to Aries Science & Technology and EB-002 to MycoMedica.
- Expanded patent estate with five new US patents for EVM301 portfolio.

## SEC filing metadata
- accession: 0001493152-24-045840
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/0001493152-24-045840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045840
- JSON: https://secwatch.observer/filing/0001493152-24-045840.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.